PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc to Discuss the Positive Opinion from the CHMP on its AADC Deficiency Gene Therapy Transcript

May 23, 2022 / 12:00PM GMT
Release Date Price: €30 (+1.35%)
Operator

Good day, and thank you for standing by. Welcome to the AADC CHMP Positive Opinion Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Kylie O'Keefe, Head of Investor Relations. Please go ahead.

Kylie O;Keefe
PTC Therapeutics, Inc. - VP, Head of Global Strategic Marketing & Business Intelligence

' -

Good morning, and thank you for joining us on the call today. Today's call will include forward-looking statements based on current expectations. Please take a moment to review the slide posted on our Investor Relations website in conjunction with the call, which contains our forward-looking statements.

During this call, we will be showing a short video which all participants can view by logging into the webcast of the call. The video can also be viewed under the Events and then Presentations and Videos in the Investors section of our website, should you not be able to access the webcast.

Today on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot